Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

Molecular Formula	C₃H₉NNa₂O₇P₂
Molecular Weight	279.03 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	278.96496419 g/mol
Monoisotopic Mass	278.96496419 g/mol
Topological Polar Surface Area	167 Å²
Heavy Atom Count	15
Formal Charge	0
Complexity	238
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

1 of 4
Drug Name	Aredia
Active Ingredient	Pamidronate disodium
Dosage Form	Injectable
Route	injection; Injection
Strength	30mg/vial; 60mg/vial; 90mg/vial
Market Status	Prescription
Company	Novartis

2 of 4
Drug Name	Pamidronate disodium
PubMed Health	Pamidronate (Injection)
Drug Classes	Calcium Regulator
Drug Label	Pamidronate Disodium is a sterile bone-resorption inhibitor available in 30 mg and 90 mg vials for intravenous administration. The pamidronate disodium obtained by combining pamidronic acid and sodium hydroxide is provided in a sterile, ready to use...
Active Ingredient	Pamidronate disodium
Dosage Form	Injectable
Route	Injection
Strength	90mg/vial; 30mg/10ml (3mg/ml); 60mg/10ml (6mg/ml); 30mg/vial; 60mg/vial; 90mg/10ml (9mg/ml)
Market Status	Prescription
Company	Pliva Lachema; Areva Pharms; Hospira; Teva Pharms Usa; Sun Pharma Global; Fresenius Kabi Usa; Luitpold; Mustafa Nevzat; Eurohlth Intl; Agila Speclts

3 of 4
Drug Name	Aredia
Active Ingredient	Pamidronate disodium
Dosage Form	Injectable
Route	injection; Injection
Strength	30mg/vial; 60mg/vial; 90mg/vial
Market Status	Prescription
Company	Novartis

4 of 4
Drug Name	Pamidronate disodium
PubMed Health	Pamidronate (Injection)
Drug Classes	Calcium Regulator
Drug Label	Pamidronate Disodium is a sterile bone-resorption inhibitor available in 30 mg and 90 mg vials for intravenous administration. The pamidronate disodium obtained by combining pamidronic acid and sodium hydroxide is provided in a sterile, ready to use...
Active Ingredient	Pamidronate disodium
Dosage Form	Injectable
Route	Injection
Strength	90mg/vial; 30mg/10ml (3mg/ml); 60mg/10ml (6mg/ml); 30mg/vial; 60mg/vial; 90mg/10ml (9mg/ml)
Market Status	Prescription
Company	Pliva Lachema; Areva Pharms; Hospira; Teva Pharms Usa; Sun Pharma Global; Fresenius Kabi Usa; Luitpold; Mustafa Nevzat; Eurohlth Intl; Agila Speclts

Find Disodium Pamidronate Pentahydrate manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

19 API Suppliers

9 USDMF

2 CEP/COS

1 JDMF

1 EU WC

4 NDC API

11 Listed Suppliers

$ API Reference Price

FINISHED DOSAGE FORMULATIONS

101 FDF Dossiers

37 FDA Orange Book

22 Europe

10 Canada

11 Australia

1 South Africa

20 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

12 SPI Pharma

1 Faran Shimi Pharmaceutical

1 Pfanstiehl

1 BASF

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

2 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

10 Chewable & Orodispersible Aids

9 Taste Masking

9 Direct Compression

4 Co-Processed Excipients

4 Parenteral

3 Disintegrants & Superdisintegrants

3 Granulation

1 API Stability Enhancers

1 Thickeners and Stabilizers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

1 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

17 Finished Drug Prices

MARKET PLACE

3 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM

1 USP

1 Others

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 105,599

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

61EXCIPIENTS BY APPLICATIONS

01

02

03

03